Fujitsu Limited has made groundbreaking strides in integrating explainable AI technology into genomic medicine and cancer treatment planning. Our new multimodal AI technologies, launched on May 9, 2024, in Kawasaki, enable the creation of knowledge graphs from diverse data formats—text, images, and numerical data—which simplify the interpretation of complex datasets.
Our technology has been rigorously tested on medical benchmarks, including lung cancer classification and breast cancer survival prediction. Impressively, it identified lung cancer types with a record accuracy of 92.1%, and improved survival prediction accuracy for breast cancer treatments to 71.8%.
This AI doesn’t just process data; it makes it understandable. For instance, it uses AI to accurately integrate genomic and pathological images to pinpoint cancer types, potentially revolutionizing treatment tailoring.
By the end of fiscal 2024, Fujitsu will make these technologies available through the Fujitsu Research Portal, enhancing access to cutting-edge resources for diverse fields beyond healthcare, like data centre management and fraud detection.
Connect me at LinkedIn Head of AI, Global Fujitsu Distinguished Engineer & Fujitsu Fellow
#AI #GenomicMedicine #CancerResearch #ExplainableAI #Fujitsu #HealthcareInnovation #TechnologyInMedicine
Welcome! I’m amitkumar Shrivastava, Head of AI, Global Fujitsu Distinguished Engineer, and Fujitsu Fellow. This blog is dedicated to exploring the latest in technology, with a focus on artificial intelligence. Here, I share insights from my work, tech travels, and ongoing projects in the AI space. Join me as we dive into cutting-edge innovations and industry updates. Reach me at LinkedIn - https://www.linkedin.com/in/amitkumar-shrivastava/. 
Leave a comment